Validation of prognostic scores for survival in cancer patients beyond first-line therapy

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Trédan, Olivier ^a   Ray Coquard, Isabelle ^a   Chvetzoff, Gisèle ^a   Rebattu, Paul ^a   Bajard, Agathe ^a   Chabaud, Sylvie ^a   Pérol, David ^a   Saba, Chadi ^a   Quiblier, Florent ^a   Blay, Jean Yves ^a   Bachelot, Thomas ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; FUNCTIONAL STATUS; HUMAN; LUNG TUMOR; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVARY TUMOR; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PROGNOSTIC SCORE; SCORING SYSTEM; SURVIVAL TIME; THROMBOCYTE COUNT; TUMOR LOCALIZATION; VALIDITY;

EID: 79952558403     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-95     Document Type: Article

References (34)

1. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N. A systematic review of physicians' survival predictions in terminally ill cancer patients. Br Med J 2003, 327:195-198.
2. Lamont E, Christakis N. Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to". JAMA 2003, 290:98-104. 10.1001/jama.290.1.98, 12837717.
3. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Viganò A, Larkin P, De Conno F, Hanks G, Kaasa S, . Steering Committee of the European Association for Palliative Care Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005, 23:6240-6248. 10.1200/JCO.2005.06.866, 16135490, Steering Committee of the European Association for Palliative Care.
4. Glare PA, Eychmueller S, McMahon P. Diagnostic accuracy of the Palliative Prognostic Score in hospitalized patients with advanced cancer. J Clin Oncol 2004, 22:4823-4828. 10.1200/JCO.2004.12.056, 15570085.
5. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P, Blay JY. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 1999, 17:2840-2846.
6. Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, Chauvin F, Droz JP, Philip T, Clavel M. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 2000, 11:151-156. 10.1023/A:1008368319526, 10761748.
7. Ray-Coquard I, Ghesquière H, Bachelot T, Borg C, Biron P, Sebban C, LeCesne A, Chauvin F, Blay JY, . ELYPSE Study Group Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001, 85:816-822. 10.1054/bjoc.2001.2011, 2375083, 11556830, ELYPSE Study Group.
8. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003, 88:1721-1726. 10.1038/sj.bjc.6600956, 2377148, 12771987.
9. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY, . Groupe Francais d'Immunotherapie Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6, from the Groupe Francais d'Immunothérapie. J Clin Oncol 2004, 22:2371-2378. 10.1200/JCO.2004.06.121, 15197198, Groupe Francais d'Immunotherapie.
10. Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C, Sebban C, Biron P, Blay JY. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004, 101:2675-2680. 10.1002/cncr.20688, 15503313.
11. Elahi MM, McMillian DC, McArdle CS, Angerson WJ, Sattar N. Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 2004, 48:171-173. 10.1207/s15327914nc4802_6, 15231451.
12. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005, 92:1834-1836. 10.1038/sj.bjc.6602591, 2361776, 15870712.
13. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008, 14:710-714. 10.1158/1078-0432.CCR-07-1044, 18245530.
14. Hsieh FY. Sample size tables for logistic regression. Stat Med 1989, 8:795-802. 10.1002/sim.4780080704, 2772439.
15. Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P, Tannock I. Predictive model for survival in patients with advanced cancer. J Clin Oncol 2008, 26:5863-5869. 10.1200/JCO.2008.17.1363, 19018082.
16. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168≥3.0.CO;2-4, 8668867.
17. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004, 23:723-748. 10.1002/sim.1621, 14981672.
18. Asola R, Huhtala H, Holli K. Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer. Breast Cancer Res Treat 2006, 100:77-82. 10.1007/s10549-006-9224-x, 16758120.
19. Braga S, Miranda A, Fonseca R, Passos-Coelho JL, Fernandes A, Costa JD, Moreira A. The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Psychooncology 2007, 16:863-868. 10.1002/pon.1140, 17245696.
20. Chow E, Fung K, Panzarella T, Bezjak A, Danjoux C, Tannock I. A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 2002, 53:1291-1302. 10.1016/S0360-3016(02)02832-8, 12128132.
21. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY, . European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009, 69:5383-2391. 10.1158/0008-5472.CAN-08-3845, 2775079, 19549917, European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
22. Bruera E, Miller MJ, Kuehn N, MacEachern T, Hanson J. Estimate of survival of patients admitted to a palliative care unit: A prospective study. J Pain Symptom Manage 1992, 7:82-86. 10.1016/0885-3924(92)90118-2, 1573289.
23. Dufresne A, Pivot X, Tournigand C, Facchini T, Altweegg T, Chaigneau L, De Gramont A. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 107:275-279. 10.1007/s10549-007-9550-7, 17380382.
24. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988, 148:1586-1591. 10.1001/archinte.148.7.1586, 3382303.
25. Maltoni M, Pirovano M, Scarpi E, Marinari M, Indelli M, Arnoldi E, Gallucci M, Frontini L, Piva L, Amadori D. Prediction of survival of patients terminally ill with cancer: Results of an Italian prospective multicentric study. Cancer 1995, 75:2613-2622. 10.1002/1097-0142(19950515)75:10<2613::AID-CNCR2820751032≥3.0.CO;2-1, 7537625.
26. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996, 14:636-639.
27. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, Sebban C, Guastalla J, Biron P, Ray-Coquard I. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998, 92:405-410.
28. Gripp S, Moeller S, Bölke E, Schmitt G, Matuschek C, Asgari S, Asgharzadeh F, Roth S, Budach W, Franz M, Willers R. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 2007, 25:3313-3320. 10.1200/JCO.2006.10.5411, 17664480.
29. Bozcuk H, Koyuncu E, Yildiz M, Samur M, Ozdogan M, Artaç M, Coban E, Savas B. A simple and accurate prediction model to estimate the intrahospital mortality risk of hospitalised cancer patients. Int J Clin Pract 2004, 58:1014-1019. 10.1111/j.1742-1241.2004.00169.x, 15605663.
30. Kikuchi N, Ohmori K, Kuriyama S, Shimada A, Nakaho T, Yamamuro M, Tsuji I. Survival prediction of patients with advanced cancer: the predictive accuracy of the model based on biological markers. J Pain Symptom Manage 2007, 34:600-606. 10.1016/j.jpainsymman.2007.06.001, 17629667.
31. Suh SY, Ahn HY. Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study. Eur J Cancer 2007, 43:1051-1059. 10.1016/j.ejca.2007.01.031, 17349786.
32. Kikuchi N, Ohmori K, Kuriyama S, Shimada A, Nakaho T, Yamamuro M, Tsuji I. Survival prediction of patients with advanced cancer: the predictive accuracy of the model based on biological markers. J Pain Symptom Manage 2007, 34:600-6. 10.1016/j.jpainsymman.2007.06.001, 17629667.
33. Goldwasser P, Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997, 50:693-703. 10.1016/S0895-4356(97)00015-2, 9250267.
34. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Philip T, Favrot M. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317-22.